Patients with PWS admitted to the hospital with COVID-19 showed increased risk of in-hospital mortality, severe disease, and mechanical ventilation.

Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company ...

77 patients with Prader-Willi syndrome who previously received open-label diazoxide choline extended-release for 2 to 4 years were randomly assigned, 1:1, to continue diazoxide choline or switch ...

US FDA Approves First Treatment for Rare Genetic Disorder Prader-Willi Syndrome By Sneha S K (Reuters ... of the drug and mixed results from a late-stage trial on its efficacy.

The FDA approved extended-release diazoxide choline (Vykat XR) to treat the intense persistent sensation of hunger in patients 4 years of age and older with Prader-Willi syndrome, maker Soleno ...

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as Vykat XR – to treat extreme hunger in patients with Prader-Willi syndrome.

on March 26 to treat hyperphagia in patients four years of age and older with Prader-Willi syndrome (PWS), is now commercially available in the U.S. Soleno has established a comprehensive support ...

March 27, 2025 – The FDA has approved a drug to treat a key symptom of a rare life-threatening genetic disorder known as Prader-Willi syndrome (PWS ... PWS affects about 1 in 15,000 babies ...

Though the exact mechanism of action is unclear, it is believed that in patients with Prader-Willi syndrome ... least square mean difference: -5.0 [-8.1, -1.8]). Prior to participating in this ...

The FDA has approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release tablets to treat hyperphagia in individuals aged four years and older with Prader-Willi syndrome (PWS). The ...